FINWIRES · TerminalLIVE
FINWIRES

SHA:688513

4 stories mentioning SHA:688513Updated 4d ago

Every FINWIRES story that references SHA:688513, newest first.

Asia

Easton Biopharmaceuticals Enrolls First Subject in HP-002 Tablets Clinical Trial

Chengdu Easton Biopharmaceuticals (SHA:688513), through unit Shanghai Chaoyang Pharmaceutical, enrolled the first subject for the clinical trial of HP-002 tablets, according to a Shanghai bourse filing on Thursday.The trial, which is in phase I/II, invited patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The drug's safety and tolerability will be tested in the patients.The pharmaceutical company's shares jumped 2% during the afternoon trade.

SHA:688513
Asia

Easton Biopharmaceuticals Shortlists Two Hypertension Drugs for China Procurement Program

Chengdu Easton Biopharmaceuticals' (SHA:688513) two products won pre-bids under China's drug procurement program, according to a Tuesday filing with the Shanghai bourse.The drugs involved include nicarpidine hydrochloride injection for emergency hypertension treatment and its bisoprolol and amlodipine tablets, also for hypertension.

SHA:688513
Asia

Easton Biopharma Gets Registration Certificate for Vitamin K1 Injection

Chengdu Easton Biopharmaceuticals' (SHA:688513) vitamin K1 injection received a drug registration certificate from China's National Medical Products Administration, according to a Shanghai bourse filing on Saturday.The biopharmaceutical company's shares dipped 10% at the close of Monday's trade.The injection is used for the treatment of vitamin K deficiency bleeding and for the prevention of vitamin K deficiency.

SHA:688513
Asia

Chengdu Easton Biopharmaceuticals Gets China Nod for Post-Operative Pain Reliever

China's drug regulator approved Chengdu Easton Biopharmaceuticals' (SHA:688513) acetaminophen/oxycodone extended-release tablets, according to a Thursday disclosure to the Shanghai Stock Exchange.The drug is indicated for moderate to severe post-operative pain.

SHA:688513

Track with the FINWIRES app suite